http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Driving Performance Experimental Analysis of Series Chopper Based EV Power Train
Kawamura, Atsuo,Guidi, Giuseppe,Watanabe, Yuki,Tsuruta, Yukinori,Motoi, Naoki,Kim, Tae-Woong The Korean Institute of Power Electronics 2012 JOURNAL OF POWER ELECTRONICS Vol.12 No.6
In this paper, the series chopper based power train for electric vehicle is proposed for aiming the increase of one battery charge driving distance. Both the motor test bench based experiments and the chassis dynamo based experiments are tested and then analyzed for EV driving performance that the proposed power train with SAZZ chopper and Quasi-PAM control scheme is compared with or without the series chopper. It is confirmed through two kinds of experimental analyses that the series chopper power train for EV can be useful to extend the driving distance if the high efficiency and the low weight of chopper are satisfied.
Driving Performance Experimental Analysis of Series Chopper Based EV Power Train
Atsuo Kawamura,Giuseppe Guidi,Yuki Watanabe,Yukinori Tsuruta,Naoki Motoi,Tae-Woong Kim 전력전자학회 2012 JOURNAL OF POWER ELECTRONICS Vol.12 No.6
In this paper, the series chopper based power train for electric vehicle is proposed for aiming the increase of one battery charge driving distance. Both the motor test bench based experiments and the chassis dynamo based experiments are tested and then analyzed for EV driving performance that the proposed power train with SAZZ chopper and Quasi-PAM control scheme is compared with or without the series chopper. It is confirmed through two kinds of experimental analyses that the series chopper power train for EV can be useful to extend the driving distance if the high efficiency and the low weight of chopper are satisfied.
Tomoo Nakagawa,Taku Kobayashi,Kiyohiro Nishikawa,Fumika Yamada,Satoshi Asai,Yukinori Sameshima,Yasuo Suzuki,Mamoru Watanabe,Toshifumi Hibi 대한장연구학회 2019 Intestinal Research Vol.17 No.4
Background/Aims: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. Methods: Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months were analyzed as of July 2018. Results: Of 523 patients in the analysis set, 372 remained on CT-P13 therapy, while 54 (20.2%) of 267 patients with Crohn’s disease, and 97 (37.9%) of 256 patients with ulcerative colitis were withdrawn during follow-up. A total of 144 adverse drug reactions (ADRs) were reported in 106 patients (20.3%). Infusion reaction was the most frequent ADR observed in 49 patients (9.4%). Efficacy parameters decreased immediately after the start of treatment in naïve patients to anti-tumor necrosis factor-α antibody. In the patients switched from originator infliximab for nonmedical reasons, the decreased parameters due to proceeded treatment with the originator were maintained in low ranges, and the treatment continuation rate was high with low ADR incidence. In contrast, in patients switched for medical reasons such as adverse event or loss of response, the incidence of ADRs was high. However, the efficacy parameters were improved, and the treatment continuation rate was not significantly different from that of the naïve patient group. Conclusions: In this interim analysis, CT-P13 was comparable to the originator infliximab with respect to ADRs and efficacy, and is therefore considered to be a cost-efficient interchangeable biosimilar for Japanese patients with inflammatory bowel disease.